FGF2 and stroke disorder: Since no attempt was made to re-engineer the neurotrophin for BBB delivery, the trials met with the expected failed results for either the intravenous fibroblast growth factor (FGF)-2 stroke trial [761] or the intravenous erythropoietin (EPO) stroke trial [762].